Fig. 4From: Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysisNo difference was observed in all-cause mortality between patients undergoing first-line allo-HSCT and those undergoing first-line ISTBack to article page